Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment
Authors:
- 8 July 2011
- journal article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 27 (3) , 193-200
Abstract
Objectives: To explore the cost-effectiveness of early biologic treatment, followed by dose-reduction in the case of remission, of active rheumatoid arthritis (RA), compared with standard treatment with methotrexate (MTX) in Sweden.Methods: Effectiveness (function, disease activity, erosions) in early RA for both alternatives was taken from a clinical trial comparing etanercept (ETA) combined with MTX to MTX alone. Patients discontinuing treatment can switch to another or their first biologic treatment. For patients in remission (Disease Activity Score [DAS28] < 2.6), ETA is reduced to half the dose. Return to full dose occurs when DAS28 reaches ≥ 3.2 again. Costs and utilities by level of functional capacity from an observational study are used. The model is analyzed as a micro-simulation and results are presented from the societal perspective for Sweden, for 10 years; costs (€2008) and effects are discounted at 3 percent. Sensitivity analysis was performed for the perspective, the time horizon, switching, and dose-reduction.Results: The main analysis conservatively assumes 50 percent switching at discontinuation. The cost per quality-adjusted life-year (QALY) gained with early ETA/MTX treatment is €13,500 (societal perspective, incremental cost of €15,500 and incremental QALYs of 1.15). With 75 percent switching, the cost per QALY gained was €10,400. Over 20 years, the cost per QALY gained was €8,200. Results were further sensitive to the time patients remained on half dose and the perspective.Conclusions and Policy Implications: This study combines clinical trial and clinical practice data to explore cost-effective treatment scenarios in early RA, including the use of biologics. Our results indicate that a situation where a considerable proportion of patients achieve remission, dose-adjustments will increase the cost-effectiveness of treatment.Keywords
This publication has 22 references indexed in Scilit:
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 2010
- Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in SwedenInternational Journal of Technology Assessment in Health Care, 2010
- Ten arguments for a societal perspective in the economic evaluation of medical innovationsThe European Journal of Health Economics, 2009
- Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritisJoint Bone Spine, 2009
- Imaging Progression despite Clinical Remission in Early Rheumatoid Arthritis Patients after Etanercept InterruptionInternational Journal of Immunopathology and Pharmacology, 2009
- EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Annals of the Rheumatic Diseases, 2007
- The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis & Rheumatism, 2005
- Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in SwedenAnnals of the Rheumatic Diseases, 2005
- Survival in rheumatoid arthritis: A population‐based analysis of trends over 40 yearsArthritis & Rheumatism, 2003
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990